# A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions

> **NCT00830336** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Azithromycin
- **DRUG:** Zithromax®

## Key facts

- **NCT ID:** NCT00830336
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830336, "A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00830336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*